Alar Pharmaceuticals Inc.
TWO: 6785.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yung-Shun Wen
- Employees
- 27
- Headquarters
- Taichung, Taiwan
- IPO year
- 2020
- Market cap
- NT$9.2B
- Website
- https://www.alarpharm.com
Loading 6785…
Loading profile data…Frequently asked questions about 6785
What does Alar Pharmaceuticals Inc. (6785.TWO) do?
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; A...
Where does 6785.TWO trade?
Alar Pharmaceuticals Inc. (6785.TWO) trades on the Taipei Exchange.
What sector is 6785.TWO in?
Alar Pharmaceuticals Inc. (6785.TWO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Alar Pharmaceuticals Inc.?
Yung-Shun Wen is the chief executive officer of Alar Pharmaceuticals Inc. (6785.TWO).
Where is Alar Pharmaceuticals Inc. headquartered?
Alar Pharmaceuticals Inc. is headquartered in Taiwan.
Does 6785.TWO pay a dividend?
Yes — Alar Pharmaceuticals Inc. (6785.TWO) paid a trailing twelve-month dividend of TWD 0.25 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6785.TWO go public?
Alar Pharmaceuticals Inc. (6785.TWO) completed its initial public offering in 2020.